MLTX – moonlake immunotherapeutics - class a ordinary shares (US:NASDAQ)
Stock Stats
News
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $66.00 price target on the stock.
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update [Yahoo! Finance]
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
Form 10-Q MoonLake Immunotherapeut For: Mar 31
Form 8-K MoonLake Immunotherapeut For: May 07
Form 10-K/A MoonLake Immunotherapeut For: Dec 31
Form DEFA14A MoonLake Immunotherapeut
Form ARS MoonLake Immunotherapeut For: Dec 31
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.